Standard Lithium Ltd vs Twist Bioscience Corp — how do they compare? Standard Lithium Ltd trades at $2.27 (market cap $523.89M), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 10.4× Standard Lithium Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SLI | TWST | |
|---|---|---|
Market Cap | $523.89M | $5.45B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $102.88 |
52-Week Low | $2.15 | $24.16 |
Enterprise Value | $383.09M | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $48.40 million for 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus remains unanimously bullish with three buy ratings, citing progress toward a final investment decision in 2026.
The investment case hinges on successful project execution, with upside potential from lithium demand and federal funding, but risks include sustained cash burn and delays. The stock's current valuation at 1.52 times book value may attract value investors, yet profitability challenges and bearish technical trends warrant caution amid high operational expenditures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →